(Q36490255)

14 August 2017

1 reference

title

Impact of obesity on treatment of chronic hepatitis C. (English)

1 reference

14 August 2017

0 references

1 reference

Michael R Charlton

1

1 reference

14 August 2017

Paul J Pockros

series ordinal

2

1 reference

14 August 2017

Stephen A Harrison

series ordinal

3

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

14 August 2017

1 reference

14 August 2017

43

1 reference

14 August 2017

1177-1186

1 reference

14 August 2017

6

1 reference

Relationships between the Body Mass Index and body composition.

14 August 2017

1 reference

Evaluation of routes of administration of interferon in cancer: a review and a proposal

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

21 January 2018

1 reference

Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis.

21 January 2018

1 reference

Leptin Promotes Differentiation and Survival of Human Dendritic Cells and Licenses Them for Th1 Priming

21 January 2018

1 reference

Prevalence and Trends in Obesity Among US Adults, 1999-2000

21 January 2018

1 reference

7 January 2021

Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.

1 reference

7 January 2021

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

1 reference

7 January 2021

Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data

1 reference

7 January 2021

Obesity and non-alcoholic fatty liver disease in chronic hepatitis C.

1 reference

7 January 2021

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

1 reference

7 January 2021

Contribution of obesity to hepatitis C-related fibrosis progression

1 reference

7 January 2021

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

7 January 2021

The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

7 January 2021

Increasing prevalence of the metabolic syndrome among u.s. Adults.

1 reference

7 January 2021

Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S.

1 reference

7 January 2021

Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation

1 reference

7 January 2021

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

7 January 2021

Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States

1 reference

7 January 2021

Obesity and its nurturing effect on hepatitis C.

1 reference

7 January 2021

Hepatitis C and nonalcoholic fatty liver disease

1 reference

7 January 2021

Non-alcoholic steatohepatitis

1 reference

7 January 2021

Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis

1 reference

7 January 2021

Nonalcoholic fatty liver disease: an agenda for clinical research

1 reference

7 January 2021

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

1 reference

7 January 2021

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

1 reference

7 January 2021

High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury

1 reference

7 January 2021

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

1 reference

7 January 2021

Diagnosis, management, and treatment of hepatitis C

1 reference

7 January 2021

How cells respond to interferons

1 reference

7 January 2021

Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

1 reference

7 January 2021

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

7 January 2021

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

1 reference

7 January 2021

Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy

1 reference

7 January 2021

New kinetic models for the hepatitis C virus

1 reference

7 January 2021

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

1 reference

7 January 2021

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

7 January 2021

Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.

1 reference

7 January 2021

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

1 reference

7 January 2021

Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial

1 reference

7 January 2021

Adipose tissue, adipokines, and inflammation

1 reference

7 January 2021

Adipose tissue and adipokines: for better or worse

1 reference

7 January 2021

A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes?

1 reference

7 January 2021

Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

1 reference

7 January 2021

Leptin, obesity and cardiovascular disease

1 reference

7 January 2021

The intricate interplay among body weight, stress, and the immune response to friend or foe.

1 reference

7 January 2021

Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression

1 reference

7 January 2021

Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.

1 reference

7 January 2021

Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells.

1 reference

7 January 2021

Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity

1 reference

7 January 2021

Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women

1 reference

7 January 2021

Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression

1 reference

7 January 2021

Adiponectin normalizes LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic ethanol feeding

1 reference

7 January 2021

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

1 reference

7 January 2021

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

1 reference

7 January 2021

Serum adiponectin concentration in patients with hepatitis C virus

1 reference

7 January 2021

Adiponectin and its receptors in patients with chronic hepatitis C.

1 reference

7 January 2021

Non-organ specific autoantibodies in children with chronic hepatitis C.

1 reference

7 January 2021

High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection.

1 reference

7 January 2021

Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease

1 reference

7 January 2021

Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year

1 reference

7 January 2021

Liver disease in patients with diabetes mellitus

1 reference

7 January 2021

How do we get fat? An epidemiologic and metabolic approach

1 reference

7 January 2021

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

1 reference

7 January 2021

Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms

1 reference

7 January 2021

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1

1 reference

7 January 2021

STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?

1 reference

7 January 2021

Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C

1 reference

7 January 2021

Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease

1 reference

7 January 2021

Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C.

1 reference

7 January 2021

Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury

1 reference

7 January 2021

The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum

1 reference

7 January 2021

Lipotoxic heart disease in obese rats: implications for human obesity

1 reference

7 January 2021

Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome

1 reference

7 January 2021

Adiponectin and its receptors in non-alcoholic steatohepatitis.

1 reference

7 January 2021

Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients

1 reference

7 January 2021

Insulin resistance and steatosis in hepatitis C virus infection.

1 reference

7 January 2021

Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis

1 reference

7 January 2021

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

7 January 2021

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

1 reference

7 January 2021

Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients

1 reference

7 January 2021

Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection.

1 reference

7 January 2021

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

1 reference

7 January 2021

Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice

1 reference

7 January 2021

Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients

1 reference

7 January 2021

In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus

1 reference

7 January 2021

Effect of interferon treatment on serum 2',5'-oligoadenylate synthetase levels in hepatitis C-infected patients

1 reference

7 January 2021

Evidence for a deficiency of interferon response in mononuclear cells from hepatitis C viremic patients

1 reference

7 January 2021

Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C.

1 reference

7 January 2021

Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes.

1 reference

7 January 2021

Hepatitis C virus NS5A protein interacts with 2',5'-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner

1 reference

7 January 2021

Lymphatic transport of proteins after subcutaneous administration

1 reference

7 January 2021

Road signs guiding leukocytes along the inflammation superhighway

1 reference

7 January 2021

The effect of patient and tumour characteristics on visualization of sentinel nodes after a single intratumoural injection of Tc 99m labelled human albumin colloid in breast cancer.

1 reference

7 January 2021

Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a.

1 reference

7 January 2021

In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy.

1 reference

7 January 2021

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

1 reference

7 January 2021

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

1 reference

7 January 2021

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

1 reference

7 January 2021

Metformin in the treatment of patients with non-alcoholic steatohepatitis

1 reference

7 January 2021

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

1 reference

7 January 2021

A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus

1 reference

7 January 2021

Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.

1 reference

7 January 2021

Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C.

1 reference

7 January 2021

Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy

1 reference

7 January 2021

Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21239

1 reference

14 August 2017

1 reference